An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non–Small-Cell Lung Cancer We assessed cancer-related molecular marker test ...
The EML250-ID and OmniMarker-ID transform underground utility management into a data-driven system that can write, ...
HOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results